Preferred Label : eburnamonine;
MeSH note : RN given refers to cpd with unspecified isomeric designation;
CISMeF synonym : eburnamenin-14(15h)-one; cervoxan;
MeSH hyponym : (-)-eburnamonine;
MeSH Related Number : vinburnine; eburnamonine phosphate, (3alpha,16alpha)-isomer; eburnamonine, (3alpha,16alpha)-isomer; eburnamonine monohydrochloride, (3alpha,16alpha)-isomer; 38521-11-8 (mono-HCl(3alpha,16alpha)-isomer); 4880-88-0 ((3alpha,16alpha)-isomer); 77117-62-5 (unspecified phosphate(3alpha,16alpha)-isomer); G54D0HMY25; 474-00-0 (eburnamonine);
Registry Number MeSH : 474-00-0;
Related CAS MeSH : 4880-88-0 (eburnamonine, (3alpha,16alpha)-isomer); 38521-11-8 (eburnamonine monohydrochloride, (3alpha,16alpha)-isomer); 77117-62-5 (eburnamonine phosphate, (3alpha,16alpha)-isomer); G54D0HMY25 (vinburnine);
related registry number list (CISMeF) : 38521-11-8 (mono-HCl(3alpha,16alpha)-isomer); 4880-88-0 ((3alpha,16alpha)-isomer);
77117-62-5 (unspecified phosphate(3alpha,16alpha)-isomer);
Codes EINECS : 207-476-0;
Is substance : O;
UNII : NPD9S131ZU;
Origin ID : C016422;
UMLS CUI : C0058904;
ATC code(s)
Automatic exact mappings (from CISMeF team)
CISMeF manual mappings
MeSH term(s) associated for indexing
Pharmacological action(s)
Record concept(s)
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
http://www.has-sante.fr/portail/jcms/c_1121568/cervoxan
http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-11/cervoxan_02-11-2011_avis_ct-11264.pdf
2011
France
French
eburnamonine
administration, oral
treatment outcome
insurance, health, reimbursement
vinca alkaloids
vasodilator agents
vinburnine
cognition disorders
aged
vision disorders
evaluation of the transparency committee
---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-07/cervoxan_-_ct-8147.pdf
http://www.has-sante.fr/portail/jcms/c_968480/cervoxan
2010
France
French
cognition disorders
aged
vision disorders
eburnamonine
administration, oral
vinburnine
vasodilator agents
vinca alkaloids
insurance, health, reimbursement
vinca alkaloids
evaluation of the transparency committee
---